Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06194448
Title To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations (NEOLA)
Acronym NEOLA
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | TUR | ISR | ESP


No variant requirements are available.